Total Payments
$164,227
2024 Payments
$237.75
Companies
14
Transactions
150
Payment Breakdown by Category
Consulting$81,642 (49.7%)
Other$47,235 (28.8%)
Travel$33,040 (20.1%)
Food & Beverage$2,310 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $81,642 | 24 | 49.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,235 | 17 | 28.8% |
| Travel and Lodging | $33,040 | 57 | 20.1% |
| Food and Beverage | $2,310 | 52 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Braeburn Pharmaceuticals, Inc. | $72,731 | 62 | $0 (2017) |
| Titan Pharmaceuticals, Inc. | $64,989 | 32 | $0 (2020) |
| Alkermes, Inc. | $5,885 | 7 | $0 (2018) |
| Orexo US, Inc. | $5,148 | 24 | $0 (2021) |
| Hikma Pharmaceuticals USA | $4,986 | 2 | $0 (2022) |
| Kaleo, Inc. | $4,070 | 8 | $0 (2018) |
| Indivior Inc. | $2,536 | 3 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,176 | 1 | $0 (2019) |
| Braeburn Inc. | $1,350 | 1 | $0 (2018) |
| Incyte Corporation | $146.14 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $237.75 | 9 | Janssen Biotech, Inc. ($98.06) |
| 2023 | $123.56 | 1 | Incyte Corporation ($123.56) |
| 2022 | $2,904 | 2 | Hikma Pharmaceuticals USA ($2,886) |
| 2021 | $21.08 | 1 | Orexo US, Inc. ($21.08) |
| 2020 | $9,187 | 6 | Titan Pharmaceuticals, Inc. ($4,668) |
| 2019 | $64,768 | 38 | Titan Pharmaceuticals, Inc. ($60,284) |
| 2018 | $9,245 | 18 | Alkermes, Inc. ($5,735) |
| 2017 | $77,741 | 75 | Braeburn Pharmaceuticals, Inc. ($72,731) |
All Payment Transactions
150 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Immunology | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.23 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Immunology | ||||||
| 07/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Immunology | ||||||
| 07/16/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: Immunology | ||||||
| 05/14/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT, ZEPBOUND | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Immunology | ||||||
| 05/01/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.58 | General |
| Category: Dermatology | ||||||
| 02/13/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: OUD | ||||||
| 11/07/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $123.56 | General |
| Category: Dermatology | ||||||
| 10/24/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2022 | Hikma Pharmaceuticals USA | Kloxxado (Drug) | Consulting Fee | Cash or cash equivalent | $2,886.05 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 08/24/2021 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $21.08 | General |
| Category: Addiction Medicine | ||||||
| 12/18/2020 | Hikma Pharmaceuticals USA | Naloxone (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 12/15/2020 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $18.56 | General |
| Category: Addiction Medicine | ||||||
| 06/13/2020 | Indivior Inc. | SUBLOCADE (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: OUD | ||||||
| 01/16/2020 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 01/16/2020 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Travel and Lodging | Cash or cash equivalent | $229.91 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 01/16/2020 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Food and Beverage | Cash or cash equivalent | $38.09 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 11/25/2019 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $4.52 | General |
| Category: Addiction Medicine | ||||||
| 11/14/2019 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 11/14/2019 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 11/14/2019 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Travel and Lodging | Cash or cash equivalent | $517.25 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 11/14/2019 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Food and Beverage | Cash or cash equivalent | $212.09 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
| 10/14/2019 | Titan Pharmaceuticals, Inc. | Probuphine (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: Maintenance Treatment of Opioid Dependence | ||||||
About Dr. Matthew Torrington, M.D
Dr. Matthew Torrington, M.D is a Addiction Medicine healthcare provider based in Culver City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568581296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Torrington, M.D has received a total of $164,227 in payments from pharmaceutical and medical device companies, with $237.75 received in 2024. These payments were reported across 150 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($81,642).
Ad
Practice Information
- Specialty Addiction Medicine
- Location Culver City, CA
- Active Since 03/27/2007
- Last Updated 07/20/2012
- Taxonomy Code 207QA0401X
- Entity Type Individual
- NPI Number 1568581296
Products in Payments
- Probuphine (Drug) $139,070
- Vivitrol 380 mg (Drug) $5,735
- Zubsolv (Drug) $5,148
- Evzio (Drug) $4,070
- Kloxxado (Drug) $2,886
- SUBLOCADE (Drug) $2,536
- Naloxone (Drug) $2,100
- OPZELURA (Drug) $146.14
- TREMFYA (Drug) $98.06
- TALTZ (Drug) $55.37
- DUPIXENT (Biological) $37.23
- VRAYLAR (Drug) $18.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.